IMBRAVE050

NCT04102098 📎

Regimen

Experimental
adjuvant atezolizumab + bevacizumab x 12 months
Control
active surveillance

Population

High-risk hepatocellular carcinoma after curative-intent resection or ablation

Key finding

RFS HR 0.72 (95% CI 0.53-0.98, P=0.012) at interim — first positive phase 3 of adjuvant therapy in HCC. Grade 3-4 AE 41% vs 13%.

Source: PMID 37871608

Timeline

    Guideline citations

    • NCCN HCC (p.50)